Skip to main content
. 2018 Feb 15;7(6):e1431086. doi: 10.1080/2162402X.2018.1431086

Figure 1.

Figure 1.

Spautin-1 exhibits selective cytotoxicity-independent autophagy. (A) Indicated cancer cell lines were treated with spautin-1 (1, 3, and 10 µM) for 24 hours and cell viability was assayed (n = 3, *p < 0.05 versus untreated group, ANOVA). (B) Image analysis of MAP1LC3B puncta formation in HCT116 and CT26 cells with or without HBSS and spautin-1 (10 uM) treatment for three hours (n = 3, *p < 0.05 versus HBSS group, unpaired t-test). (C) Western blot analysis of MAP1LC3B expression in HCT116 cells with or without HBSS, spautin-1 (10 uM), and chloroquine (50 µM) treatment for three hours (n = 3, *p < 0.05 versus HBSS group, unpaired t-test). (D) Indicated cells were treated with spautin-1 (10µM), 3-methyladenine (1 mM), LY294002 (1µM), chloroquine (50µM), and bafilomycin A1 (100 nM) for 24 hours and cell viability was assayed (n = 3, *p < 0.05 versus untreated group, unpaired t-test). (E) Indicated cells were treated with oxaliplatin (50µM) or 5-fluorouracil (15µM) in the absence or presence of 3-methyladenine (1 mM), LY294002 (1µM), chloroquine (50µM), and bafilomycin A1 (100 nM) for 24 hours and then cell viability was assayed (n = 3, *p < 0.05, ANOVA). (F) Q-PCR analysis gene expression in indicated HCT116 cells (n = 3, *p < 0.05 versus control shRNA group, unpaired t-test). (G) Cell viability was assayed in indicated HCT116 cells following spautin-1(10 uM) treatment for 24 hours (n = 3).